Showing results (151-160 of 2,104) with videos related to
Sort By:
Pageof 211
CNS Drugs|June 30, 2004
The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatmentCeri J PhillipsCNS Drugs|June 30, 2004
What are the treatment options for patients with severe Alzheimer's disease?Thierry Voisin, Emma Reynish, Florence Portet, et al.CNS Drugs|September 6, 2022
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label StudyJai Perumal, Roumen Balabanov, Ray Su, et al.CNS Drugs|September 25, 2019
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use DisordersEwa Galaj, Zheng-Xiong XiCNS Drugs|September 27, 2019
Recent Advances in Pharmacotherapy for Episodic MigraineCalvin Chan, Peter J GoadsbyCNS Drugs|December 22, 2021
Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled TrialsGerard J Meskill, Craig W Davis, Donna Zarycranski, et al.CNS Drugs|December 23, 2021
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying TreatmentDejan Jakimovski, Samreen Awan, Svetlana P Eckert, et al.CNS Drugs|December 20, 2021
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in SchizophreniaArne W Mould, Noura Al-Juffali, Annette von Delft, et al.CNS Drugs|July 27, 2019
Immune Globulin Subcutaneous (Human) 20% (Hizentra®): A Review in Chronic Inflammatory Demyelinating PolyneuropathyYvette N Lamb, Yahiya Y Syed, Sohita DhillonCNS Drugs|August 15, 2019
Targeting Mitochondria in Alzheimer Disease: Rationale and PerspectivesChiara Lanzillotta, Fabio Di Domenico, Marzia Perluigi, et al.Pageof 211